Lung Cancer
Volume 69, Issue 1 , Pages 86-93 , July 2010

Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial

  • Nicolas Girard

      Affiliations

    • Department of Radiotherapy-Oncology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Université Claude Bernard-Lyon 1, Lyon, France
    • French-speaking Intergroup of Thoracic Oncology (IFCT), Paris, France
    • ,
  • Françoise Mornex

      Affiliations

    • Department of Radiotherapy-Oncology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Université Claude Bernard-Lyon 1, Lyon, France
    • French-speaking Intergroup of Thoracic Oncology (IFCT), Paris, France
    • ,
  • Jean-Yves Douillard

      Affiliations

    • French-speaking Intergroup of Thoracic Oncology (IFCT), Paris, France
    • Department of Medical Oncology, Centre René Gauducheau, Saint-Herblain, France
    • ,
  • Nadine Bossard

      Affiliations

    • Department of Epidemiology and Biostatistics, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Université Claude Bernard-Lyon 1, Lyon, France
    • ,
  • Elisabeth Quoix

      Affiliations

    • French-speaking Intergroup of Thoracic Oncology (IFCT), Paris, France
    • Department of Respiratory Medicine, Centre Hospitalier Universitaire de Strasbourg, France
    • ,
  • Véronique Beckendorf

      Affiliations

    • French-speaking Intergroup of Thoracic Oncology (IFCT), Paris, France
    • Centre Alexis Vautrin, Vandoeuvre-les-Nancy, Paris, France
    • ,
  • Dominique Grunenwald

      Affiliations

    • French-speaking Intergroup of Thoracic Oncology (IFCT), Paris, France
    • Department of Thoracic Surgery, Hôpital Tenon, Paris, France
    • ,
  • Elodie Amour

      Affiliations

    • French-speaking Intergroup of Thoracic Oncology (IFCT), Paris, France
    • ,
  • Bernard Milleron

      Affiliations

    • French-speaking Intergroup of Thoracic Oncology (IFCT), Paris, France
    • Department of Respiratory Medicine and Thoracic Oncology, Hôpital Tenon, Paris, France
    • Corresponding Author InformationCorresponding author at: Service de Pneumologie, Assistance Publique - Hôpitaux de Paris, Hôpital Tenon, 4, rue de la Chine, 75020 Paris, France. Tel.: +33 1 56 01 62 04; fax: +33 1 56 01 70 02.

Received 28 July 2009 ,Revised 24 September 2009 ,Accepted 1 October 2009.

References 

  1. American Cancer Society: Cancer Facts And Figures. Atlanta (GA): American Cancer Society; 2007;
  2. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. International association for the study of lung cancer international staging committee; participating institutions. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2:706–714
  3. Groome PA, Bolejack V, Crowley JJ, Kennedy C, Krasnik M, Sobin LH, et al. IASLC International Staging Committee; Cancer Research And Biostatistics; Observers To The Committee; Participating Institutions. The IASLC lung cancer staging project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:694–705
  4. Girard N, Mornex F. Radiotherapy for locally advanced non-small cell lung cancer. Eur J Cancer. 2009;45S1:113–125
  5. Andre F, Grunenwald D, Pignon JP, Dujon A, Pujol JL, Brichon PY, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol. 2000;18:2981–2989
  6. Martini N, Flehinger B. The role of surgery in N2 lung cancer. Surg Clin North Am. 1987;67:1037–1049
  7. Roth J, Fossella F, Komaki R. A randomized trial comparing preoperative chemotherapy and surgery with surgery alone in resectable stade III non-small cell lung cancer. J Natl Cancer Inst. 1994;86:673–680
  8. Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto a , et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994;330:153–158
  9. The International Adjuvant Lung Cancer Trial Collaborative Group . Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351–360
  10. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7:719–727
  11. Berghmans T, Paesmans M, Meert AP, Mascaux C, Lothaire P, Lafitte JJ, et al. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer. 2005;49:13–23
  12. Gilligan D, Nicolson M, Smith I, Groen H, Dalesio O, Goldstraw P, et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet. 2007;369:1929–1937
  13. Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B, et al. French thoracic cooperative group. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol. 2002;20:247–253
  14. Betticher DC, Hsu Schmitz SF, Tötsch M, Hansen E, Joss C, von Briel C, et al. Swiss Group for Clinical Cancer Research (SAKK). Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer. 2006;94:1099–1106
  15. Weiden PL, Piantadosi S. Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small cell lung cancer. A phase 2 study of the LCSG. Chest. 1994;106:344S–347S
  16. Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT, Weick JK, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 1995;13:1880–1892
  17. Eberhardt W, Wilke H, Stamatis G, Stuschke M, Harstrick A, Menker H, et al. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol. 1998;16:622–634
  18. Thomas M, Rübe C, Semik M, von Eiff M, Freitag L, Macha HN, et al. Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer. J Clin Oncol. 1999;17:1185–1193
  19. Stamatis G, Eberhardt W, Stuben G, Bildat S, Dahler O, Hillejan L. Preoperative chemoradiotherapy and surgery for selected non-small cell lung cancer IIIB subgroups: long-term results. Ann Thorac Surg. 1999;68:1144–1149
  20. Faber LP, Kittle CF, Warren WH, Bonomi PD, Taylor SG, Reddy S, et al. Preoperative chemotherapy and irradiation for stage III non-small cell lung cancer. Ann Thorac Surg. 1989;47:669–675
  21. Strauss GM, Herndon JE, Sherman DD, Mathisen DJ, Carey RW, Choi NC, et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. J Clin Oncol. 1992;10:1237–1244
  22. Deutsch M, Crawford J, Leopold K, Wolfe W, Foster W, Herndon J, et al. Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non-small cell lung cancer. Cancer. 1994;74:1243–1252
  23. Choi NC, Carey RW, Daly W, Mathisen D, Wain J, Wright C, et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol. 1997;15:712–722
  24. WHO . Histological classification of tumours of the lung. In:  Travis WB,  Brambilla A,  Muller-Hermelinck HK,  Harris CC editor. World health organization classification of tumours. pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon (France): IARC Press; 2004;
  25. Mountain C. Revisions in the international system for staging lung cancer. Chest. 1997;111:1710–1717
  26. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest. 1997;111:1718–1723
  27. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol. 1982;5:649–655
  28. Giraud P, Antoine M, Larrouy A, Milleron B, Callard P, De Rycke Y, et al. Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. Int J Radiat Oncol Biol Phys. 2000;48:1015–1024
  29. Graham MV, Purdy JA, Emami B, Harms W, Bosch W, Lockett MA, et al. Clinical dose–volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 1999;45:323–329
  30. WHO handbook for reporting results of cancer treatment. Geneva (Switzerland): World Health Organization offset Publication No. 48; 1979;
  31. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0. Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176–181
  32. Pavy JJ, Denekamp J, Letschert J, Littbrand B, Mornex F, Bernier J, et al. EORTC late effects working group. Late Effects toxicity scoring: the SOMA-LENT scale. Int J Radiat Oncol Biol Phys. 1995;31:1043–1047
  33. Bellissant E, Benichou J, Chastang C. The group sequential triangular test for phase II cancer clinical trials. Am J Clin Oncol. 1996;19:422–430
  34. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343–346
  35. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  36. Bardet E, Moro-Sibilot D, Le Chevalier T, Massard G, Douillard JY, Theobald S, et al. Standards, options and recommendations for the management of locally advanced non-small cell lung carcinoma. Bull Cancer. 2001;88:369–387
  37. Nakamura H, Taguchi M, Kitamura H, Nishikawa J. Fluorodeoxyglucose positron emission tomography integrated with computed tomography to determine resectability of primary lung cancer. Gen Thorac Cardiovasc Surg. 2008;56:404–409
  38. Grunenwald DH, André F, Le Péchoux C, Girard P, Lamer C, Laplanche A, et al. Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or N3) non-small cell lung cancer. J Thorac Cardiovasc Surg. 2000;122:796–802
  39. DeCamp MM, Rice TW, Adelstein DJ, Chidel MA, Rybicki LA, Murthy SC, et al. Value of accelerated multimodality therapy in stage IIIA and IIIB non-small cell lung cancer. J Thorac Cardiovasc Surg. 2003;126:17–27
  40. Trodella L, Granone P, Valente S, Margaritora S, Macis G, Cesario A, et al. Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA–IIIB) non-small-cell lung cancer: long-term results according to downstaging. Ann Oncol. 2004;15:389–398
  41. Vokes EE, Herndon JE, 2nd , Crawford J, Leopold KA, Perry MC, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol. 2002;20:4191–4198
  42. Fleck J, Camargo J, Godoy D, Teixeira P, Graga-Filho A, Barletta A. Chemoradiation therapy alone versus chemotherapy alone as a neoadjuvant treatment for stage III non-small-cell lung cancer. Preliminary report of a phase III, randomized trial. Proc Am Soc Clin Oncol. 1993;11:1108;(abstract)
  43. Thomas M, Rübe C, Hoffknecht P, Macha HN, Freitag L, Linder A, et al. German Lung Cancer Cooperative Group. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol. 2008;9:636–648
  44. Van Zandwijk N, Smit EF, Kramer GW, Schramel F, Gans S, Festen J, et al. Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). J Clin Oncol. 2000;18:2658–2664
  45. Albain KS, Swann RS, Rusch VW, Turrisi AT, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374:379–386
  46. van Meerbeeck JP, Kramer GW, Van Schil PE, Legrand C, Smit EF, Schramel F, et al. European organisation for research and treatment of cancer-lung cancer group. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst. 2007;99:442–450
  47. Betticher DC, Hsu Schmitz SF, Tötsch M, Hansen E, Joss C, von Briel C, et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol. 2003;21:1752–1759

PII: S0169-5002(09)00502-9

doi: 10.1016/j.lungcan.2009.10.003

Lung Cancer
Volume 69, Issue 1 , Pages 86-93 , July 2010

Article Tools

* Image Usage & Resolution